Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 310 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mesenchymal stem cell Clear all
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional

Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds

NCT01751282
View directory record Official record
Conditions
Non Healing Wounds
Interventions
Stem Cell
Genetic
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional Results available

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

NCT03857841
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
UNEX-42, Phosphate-buffered saline
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
3 Days to 14 Days
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 13, 2026, 2:34 PM EDT
Suspended Phase 1 Interventional

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

NCT02962661
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Not applicable Interventional

Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration

NCT03014037
View directory record Official record
Conditions
Osteoarthritis
Interventions
Unilateral Bone Marrow Procurement, Bilateral Bone Marrow Procurement
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 13, 2026, 2:34 PM EDT
Withdrawn Phase 1 Interventional

Stem Cells for the Treatment of Pouchitis

NCT05578508
View directory record Official record
Conditions
Pouchitis, Crohn's Disease, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Pouch, Ileal
Interventions
Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 1 Interventional

Alzheimer's Disease Stem Cells Multiple Infusions

NCT04040348
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Approximately 100 million cells allogeneic hMSC
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
50 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

NCT03840343
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
Interventions
Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 13, 2026, 2:34 PM EDT
Not listed Phase 1 Interventional

Stem Cell Study for Long COVID-19 Neurological Symptoms

NCT06156241
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Stem Cell
Biological
Lead sponsor
Charles Cox
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 13, 2026, 2:34 PM EDT
Not listed Phase 2 Interventional

Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis

NCT04448106
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis Shoulder
Interventions
Celltex- AdMSCs
Biological
Lead sponsor
Celltex Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 13, 2026, 2:34 PM EDT
Active, not recruiting Phase 1 Interventional

Angiographic Delivery of AD-MSC for Ulcerative Colitis

NCT04312113
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adipose derived, autologous mesenchymal stem cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Terminated Phase 2 Interventional Results available

Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device

NCT03925324
View directory record Official record
Conditions
Ischemic Heart Disease, Non-ischemic Cardiomyopathy
Interventions
Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Placebo
Biological · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 13, 2026, 2:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study

NCT07304440
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione
Biological · Drug
Lead sponsor
Adia Med of Winter Park LLC
Other
Eligibility
3 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Winter Park, Florida • Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke

NCT01849887
View directory record Official record
Conditions
Ischemic Stroke
Interventions
bone marrow-derived mesenchymal stem cells, Placebo
Biological · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 13, 2026, 2:34 PM EDT
Recruiting Phase 1 Interventional

Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

NCT07226726
View directory record Official record
Conditions
Congenital Myasthenic Syndrome
Interventions
AlloEx exosomes
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Naples, Florida • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 13, 2026, 2:34 PM EDT
Terminated Phase 1 Interventional

Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

NCT05130983
View directory record Official record
Conditions
Crohn Disease, Inflammatory Bowel Diseases
Interventions
ExoFlo
Biological
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure

NCT02467387
View directory record Official record
Conditions
Non-Ischemic Heart Failure
Interventions
Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer's Solution
Drug
Lead sponsor
CardioCell LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.

NCT03265808
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
allogeneic human mesenchymal stem cells (allo-hMSCs), Placebo
Drug
Lead sponsor
Ihsan M Salloum, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

NCT00562497
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Corticosteroid
Drug · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

NCT03799718
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
NurOwn (MSC-NTF cells)
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Redwood City, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 13, 2026, 2:34 PM EDT
Completed Phase 2 Interventional

Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty

NCT03169231
View directory record Official record
Conditions
Aging Frailty
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Biological · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
70 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Aventura, Florida • Coral Gables, Florida • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 13, 2026, 2:34 PM EDT